Literature DB >> 33662385

Induction and Long-term Follow-up With ABX464 for Moderate-to-severe Ulcerative Colitis: Results of Phase IIa Trial.

Séverine Vermeire1, Xavier Hébuterne2, Herbert Tilg3, Gert De Hertogh4, Paul Gineste4, Jean-Marc Steens4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33662385     DOI： 10.1053/j.gastro.2021.02.054

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  4 in total

1.  IBD therapeutics: what is in the pipeline?

Authors:  Alexandros Toskas; Ayesha Akbar
Journal:  Frontline Gastroenterol       Date:  2022-06-15

2.  Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study.

Authors:  Claire Daien; Marek Krogulec; Paul Gineste; Jean-Marc Steens; Laurence Desroys du Roure; Sophie Biguenet; Didier Scherrer; Julien Santo; Hartmut Ehrlich; Patrick Durez
Journal:  Ann Rheum Dis       Date:  2022-05-31       Impact factor: 27.973

3.  Novel Therapies and Approaches to Inflammatory Bowel Disease (IBD).

Authors:  Federica Furfaro; Elisa Ragaini; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  J Clin Med       Date:  2022-07-28       Impact factor: 4.964

Review 4.  Small Molecule Drugs in Inflammatory Bowel Diseases.

Authors:  Inès Ben Ghezala; Maëva Charkaoui; Christophe Michiels; Marc Bardou; Maxime Luu
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.